Serological markers of inflammatory bowel disease

Biochemia Medica

Volumn 23, Issue 1, 2013, Pages 28-42

  Kuna, Andrea Tešija ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Colitis; Crohn disease; Inflammatory bowel disease; Serological tests; Ulcerative

Indexed keywords

ALPHA ENOLASE; ANTIBODY; AUTOANTIBODY; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BETA GLUCURONIDASE; CATALASE; CATHEPSIN G; CBIR1 FLAGELLIN ANTIBODY; CHITIN ANTIBODY; CHITOBIOSIDE CARBOHYDRATE ANTIBODY; ELASTASE; EXOCRINE PANCREAS AUTOANTIBODY; FUNGUS ANTIBODY; GOBLET CELL ANTIBODY; HISTONE H1; I2 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LACTOFERRIN; LAMINARIBIOSIDE CARBOHYDRATE ANTIBODY; LAMINARIN ANTIBODY; MANNAN; MANNOBIOSIDE CARBOHYDRATE ANTIBODY; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONHISTONE PROTEIN; OUTER MEMBRANE PORIN C ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE COURSE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GOBLET CELL; HUMAN; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MUTATION; PERMEABILITY; PHENOTYPE; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; REVIEW; RISK; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84873550266     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2013.006     Document Type: Review

References (99)

1. Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med 2011; 365:1713-25. http://dx.doi.org/10.1056/NEJMra1102942.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. http://dx.doi.org/10.1056/NEJMra020831.
3. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician 2011;84:1365-75.
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78. http://dx.doi.org/10.1056/NEJ-Mra0804647.
5. Hannauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-S9. http://dx.doi.org/10.1097/01.MIB.0000195385.19268.68.
6. Travis SP, Stange EF, Lemann M, Öresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(Suppl 1):i16-i35. http://dx.doi.org/10.1136/gut.2005.081950b.
7. Stange EF, Travis SPL, Vermiere S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55(Suppl 1):i1-i15. http://dx.doi.org/10.1136/gut.2005.081950a.
8. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):v1-v16. http://dx.doi.org/10.1136/gut.2004.043372.
9. Mokrowiecka A, Kumor A, Jakubczyk E, Pietruczuk M, Malecka-Panas E. The application of Montreal classification in different clinical and serological IBD subtypes. Hepatogastroenterology 2010;57:787-93.
10. Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med 2010;122:177-85. http://dx.doi.org/10.3810/pgm.2010.07.2184.
11. Tsianos EV, Katsanos K. Do we really understand what immunological disturbances in inflammatory bowel disease mean? World J Gastroenterol 2009;15:521-55. http://dx.doi.org/10.3748/wjg.15.521.
12. Hart AL, Ng SC, Mann E, Al-Hassi HO, Bernardo D, Knight SC. Homing of immune cells: Role in homeostasis and intestinal inflammation. Inflamm Bowel Dis 2010;16:1969-77. http://dx.doi.org/10.1002/ibd.21304.
13. Mudter J. Innate and adaptive immunity in inflammatory bowel disease. World J Gastroenterol 2011;17:3178-83.
14. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006;12:4807-12.
15. Homsak E, Micetic-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value. Wien Klin Wochenschr 2010;122(Suppl 2):19-25. http://dx.doi.org/10.1007/s00508-010-1344-y.
16. Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: Practical consideration for clinicians. Gastroenterol Clin Biol 2009;33(Suppl 3):S158-73. http://dx.doi.org/10.1016/S0399-8320(09)73151-3.
17. Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, Colombel JF. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003;17:19-35. http://dx.doi.org/10.1053/bega.2002.0347.
18. Dotan N, Altstock RT, Schwarz M, Dukler A. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus 2006;15:442-50. http://dx.doi.org/10.1191/0961203306lu2331oa.
19. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Serum Anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010;16:1367-75.
20. Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996;3:219-26.
21. Ukabam SO, Clamp JR, Cooper BT. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 1983;27:70-4. http://dx.doi.org/10.1159/000198932.
22. McKenzie H, Parrat D, Main J, Pennington CR. Antigenic heterogeneity of strains of Saccharomyces cerevisiae and Candida albicans recognised by serum antibodies from patients with Crohn's disease. FEMS Microbiol Immunol 1992;89:219- 24. http://dx.doi.org/10.1111/j.1574-6968.1992.tb04997.x.
23. Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology 2006;130:1764-75. http://dx.doi.org/10.1053/j.gastro.2006.02.009.
24. Wayne LG, Hollander D, Anderson B, Sramek HA, Vadheim CM, Rotter JI. Immunoglobulin A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. J Clin Microbiol 1992;30:2013-8.
25. Nakamura RM, Matsutani M, Barry M. Advances in clinical laboratory tests for inflammatory bowel disease. Clin Chim Acta 2003;335:9-20. http://dx.doi.org/10.1016/S0009-8981-(03)00286-9.
26. Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012;18:1340-55. http://dx.doi.org/10.1002/ibd.21903.
27. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006;52:171-81. http://dx.doi.org/10.1373/clinchem.2005.058560.
28. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord 2004;4:167-74.
29. Desplat-Jego S, Johanet C, Escande A, Goetz J, Fabien N, Olsson N, et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol 2007;13:2312-8.
30. Mokrowiecka A, Daniel P, Slomka M, Majak P, Panas EM. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology 2009;56:162-6.
31. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006;131:366-78. http://dx.doi.org/10.1053/j.gastro.2006.04.030.
32. Mizoguchi E. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008;14:5115-24. http://dx.doi.org/10.3748/wjg.14.5115.
33. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis 2010;28:418-23. http://dx.doi.org/10.1159/000320396.
34. Seow CH, Stempak JM, Xu W, Stat P, Lan H, Griffiths AM, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009;104:1426-34. http://dx.doi.org/10.1038/ajg.2009.79.
35. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000;68:1542-8. http://dx.doi.org/10.1128/IAI.68.3.1542-1548.2000.
36. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbialantigens. Gastroenterology 2002;123:689-99. http://dx.doi.org/10.1053/gast.2002.35379.
37. Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut 2006;55:1667-9. http://dx.doi.org/10.1136/gut.2005.089623.
38. Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000;119:23-31. http://dx.doi.org/10.1053/gast.2000.8519.
39. Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immun 2002;70:6567-75. http://dx.doi.org/10.1128/IAI.70.12.6567-6575.2002.
40. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan S., et al. Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest 2004;113:1296-306.
41. Savige J, Dimech W, Fritzler M, Goeken J, Hagen C, Jennette C, et al. Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies. Quality Control Guidelines, Comments, and Recommendations for Testing in Other Autoimmune Diseases. Am J Clin Pathol 2003;120:312-8. http://dx.doi.org/10.1309/WA-EPADW0K4LPUHFN.
42. Kallenberg CGM, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2:661-70. http://dx.doi.org/10.1038/ncprheum0355.
43. Editorial. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology 2002;41:481-3. http://dx.doi.org/10.1093/rheumatology/41.5.481.
44. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86:202-10. http://dx.doi.org/10.1016/S0091-6749-(05)80067-3.
45. Rump JA, Schölmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990;181:406-13. http://dx.doi.org/10.1016/S0171-2985(11)80509-7.
46. Billing P, Tahir S, Cifin B, Gagne G, Cobb L, Targan S., et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995;147:979-87.
47. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNAse treatment of neutrophils: ulcerative colitis, type I autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995;15:293-9. http://dx.doi.org/10.1007/BF01541319.
48. Teegen B, Niemann S, Probst C, Schlumberger W, Stöcker W, Komorowski L. DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. Contemporary Challenges in Autoimmunity: Ann N Y Acad Sci 2009;1173:161-5. http://dx.doi.org/10.1111/j.1749-6632.2009.04752.x.
49. Stöcker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stöcker K, et al. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1987;22(Suppl 139):41-52. http://dx.doi.org/10.3109/00365528709089774.
50. Seibold F, Mörk H, Tanza S, Müller A, Holzhüter C, Weber P, Scheurlen M. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997;40:481-4.
51. Roggenbuck D, Hausdorf D, Martinez-Gamboa I, Reinhold D, Büttner T, Jungblut PR, et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 2009;58:1620-8. http://dx.doi.org/10.1136/gut.2008.162495.
52. Terahara K, Yoshida M, Igarashi S, Nochi T, Soares Pontes G, Hase K, et al. Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells. J Immunol 2008;180:7840-6.
53. Ohno H, Hase K. Glycoprotein 2 (GP2) grabbing the FimH+ bacteria into M cells for mucosal immunity. Gut Microbes 2010;1:407-10. http://dx.doi.org/10.4161/gmic.1.6.14078.
54. Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol 2008;52:2-12. http://dx.doi.org/10.1111/j.1574-695X.2007.00359.x.
55. Hibi T, Ohara M, Kobayashi K, Brown WR, Toda K, Takaishi H, et al. Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut 1994;35:224-30. http://dx.doi.org/10.1136/gut.35.2.224.
56. Lakatos L, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis 2009;15:365-74. http://dx.doi.org/10.1002/ibd.20778.
57. Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 2004;10:771-7. http://dx.doi.org/10.1097/00054725-200411000-00012.
58. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 2007;13:24-32. http://dx.doi.org/10.1002/ibd.20047.
59. Grzybowska-Chlebowczyk U, Wos H, Sieron AL, Wiecek S, Augusciak-Duma A, Koryciak-Komarska H, Kasznia-Kocot J. Serologic investigation in children with inflammatory bowel disease and food allergy. Mediators Inflamm 2009; 512695. http://dx.doi.org/10.1155/2009/512695.
60. Basta Z, Csi I, Szabo G, Szegedi G. Seroreactovity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. World J Gastroenterol 2003;9:2380-12.
61. Granito A, Zauli D, Muratori P, Muratori L, Grassi A, Bortolotti R, et al. Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment Pharmacol Ther 2005;21:881-7. http://dx.doi.org/10.1111/j.1365-2036.2005.02417.x.
62. Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm Bowel Dis 2006;12:258-62. http://dx.doi.org/10.1097/01.MIB.0000215093.62245.b9.
63. Joossens S, Reinisch W, Vermiere S, Sendid B, Poulain D, Peeters M, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-7. http://dx.doi.org/10.1053/gast.2002.32980.
64. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis 2010;16:263-74.
65. Lawrance IC, Hall A, Leong R, Pearce C, Murray K. A Comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 2005;11:890-7. http://dx.doi.org/10.1097/01.MIB.0000182872.76434.8c.
66. Kovacs M, Lakatos PL, Papp M, Jacobsen S, Nemes E, Polgar M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease (IBD). J Pediatr Gastroenterol Nutr 2012;55:429-35. http://dx.doi.org/10.1097/MPG.0b013e318256b516.
67. Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, et al. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:645-51. http://dx.doi.org/10.1002/ibd.20368.
68. Targan S., Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005;128:2020-8. http://dx.doi.org/10.1053/j.gastro.2005.03.046.
69. Markowitz J, Kugathasan S, Dubinsky M, Mei L, Crandall W, LeLeiko N, et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis 2009;15:714-9. http://dx.doi.org/10.1002/ibd.20831.
70. Stöcker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stöcker K, et al. Autoimmunity to Pancreatic Juice in Crohn's Disease Results of an Autoantibody Screening in Patients with Chronic Inflamm Bowel Dis. Scand J Gastroenterol 1987;22:41-52. http://dx.doi.org/10.3109/00365528709089774.
71. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53. http://dx.doi.org/10.1136/gut.2005.082909.
72. Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, et al. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss cohort. Inflamm Bowel Dis 2009;15:1358-67. http://dx.doi.org/10.1002/ibd.20892.
73. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91. http://dx.doi.org/10.1136/gut.42.6.788.
74. Koutroubakis IE, Petinaki E, Mouzas IA, Vlachonikolis IG, Anagnostopoulou E, Castanas E, et al. Anti-saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterology 2001;96:449-54.
75. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006;101:645-52. http://dx.doi.org/10.1111/j.1572-0241.2006.00468.x.
76. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004;53:1117-22. http://dx.doi.org/10.1136/gut.2003.030734.
77. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96. http://dx.doi.org/10.1136/gut.47.4.487.
78. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008;103:665-81. http://dx.doi.org/10.1111/j.1572-0241.2007.01652.x.
79. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414-24. http://dx.doi.org/10.1053/j.gastro.2003.11.015.
80. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56:1394-403. http://dx.doi.org/10.1136/gut.2006.108043.
81. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006;101:360-7. http://dx.doi.org/10.1111/j.1572-0241.2006.00456.x.
82. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;6:1105-11. http://dx.doi.org/10.1016/j.cgh.2008.04.032.
83. Klebl FH, Bataille F, Huy C, Hofstädter F, Schölmerich J, Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol 2005;17:73-7. http://dx.doi.org/10.1097/00042737-200501000-00015.
84. Oudkerk Pool M, Ellerbroek PM, Ridwan BU, Goldschmeding R, von Blomberg BM, Pena AS, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993;34:46-50. http://dx.doi.org/10.1136/gut.34.1.46.
85. Høie O, Aamodt G, Vermeire S, Bernklev T, Odes S, Wolters FL, et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. Journal of Crohn's and Colitis 2008;2:114-22. http://dx.doi.org/10.1016/j.crohns.2007.10.001.
86. Vecchi M, Bianchi MB, Sinico RA, Radice A, Meucci G, Torgano G, et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 1994;55:34-9. http://dx.doi.org/10.1159/000201120.
87. Sandborn WJ, Landers CJ, William BS, Tremaine J, Targan S. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996;71:431-6. http://dx.doi.org/10.4065/71.5.431.
88. Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, et al. Disease activity, ANCA, and IL23R genotype status determine early response to Infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105:1811-9. http://dx.doi.org/10.1038/ajg.2010.95.
89. Dendrinos KG, Becker JM, Stucch AF, Saubermann LJ, La-Morte W, Farraye FA. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following iIleal pouch-anal anastomosis. J Gastrointest Surg 2006;10:1060-4. http://dx.doi.org/10.1016/j.gassur.2006.02.004.
90. Melmed GY, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasiliauskas EA, Papadakis KA, et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008;51:100-8. http://dx.doi.org/10.1007/s10350-007-9158-3.
91. Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaiennie J, Abreu-Martin MT, Targan SR. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001;49:671-7. http://dx.doi.org/10.1136/gut.49.5.671.
92. Reumaux D, Colombel JF, Masy E, Duclos B, Heresbach D, Belakhe J, et al. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis 2000;6:270-4.
93. Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002;97:1458-62. http://dx.doi.org/10.1111/j.1572-0241.2002.05689.x.
94. Sendid B, Quinton JF, Charrier G, Goulet O, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998;93:1306-10. http://dx.doi.org/10.1111/j.1572-0241.1998.00415.x.
95. Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 2001;36:196-201. http://dx.doi.org/10.1080/003655201750065960.
96. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6. http://dx.doi.org/10.1136/gut.2004.060228.
97. Joossens M, Van Steen K, Branche J, Sendid B, Rutgeers P, Vasseur F, et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis 2010;16:58-67.
98. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterology 2008;14:5115-24. http://dx.doi.org/10.3748/wjg.14.5115.
99. Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV, Burek CL, Datta L, Nouvet F. Antibodies to Saccharomyces cerevisiae in Crohn's disease: Higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007;13:143-51. http://dx.doi.org/10.1002/ibd.20031.